No, it aint gonna fall ro 45 cents because at $1.12 its already insanely cheap with all negatives priced in. But they are cowards.
Hiring experienced marketing people lots of things in the pipeline, people got too focused on the legal side.
Two dozen companies looking at EV3.
Plus if the cellphone thing takes off NLST will be $20.
I have made a lot of money buying good old NLST before the annual November small cap pump, and looking for a repeat.
Good luck to all
SMSI strongest quarters are Q3 and Q4.
With $1.30 cash per share and a blockbuster drug, anyone who thinks this will stay below $1 for any period of time is an idiot.
Low float stocks have less liquify and hence get hit the hardest in recent biotech selloff.
Two major catalysts plus Institutions buying back shares sold for tax purposes will provide a violent rebound.
Biotechs have been hammered the last 2 months.
Usually August and September are bad months for small caps as tax loss selling occurs. Usually a big rebound in November when institutions buy back.
Biotechs with small floats like SGNL have been hit the hardest, and will bounce back the fastest.
Options are always priced lower than fair market value as an incentive for management. This is huge. This means WPCS believes fair market value is much higher.
Sebastian Giordano, WPCS International Incorporated's Interim CEO and a director of the company, just received 1,000,000 options from the company. The strike price of the options received was $1.32, and these expire on September 29, 2025. Giordano now owns at least 1,075,130 options on the company.